Analysts forecast that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) will post earnings per share (EPS) of $3.59 for the current quarter, Zacks reports. Eight analysts have made estimates for Vertex Pharmaceuticals’ earnings. The lowest EPS estimate is $3.32 and the highest is $3.83. Vertex Pharmaceuticals posted earnings per share of $2.98 during the same quarter last year, which would indicate a positive year over year growth rate of 20.5%. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Vertex Pharmaceuticals will report full-year earnings of $14.58 per share for the current financial year, with EPS estimates ranging from $14.12 to $15.23. For the next financial year, analysts forecast that the business will report earnings of $15.34 per share, with EPS estimates ranging from $14.14 to $17.51. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Vertex Pharmaceuticals.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last posted its earnings results on Wednesday, January 26th. The pharmaceutical company reported $3.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.91 by $0.27. Vertex Pharmaceuticals had a net margin of 30.92% and a return on equity of 32.33%. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $1.99 billion. During the same period last year, the business posted $2.22 earnings per share.
In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 15,789 shares of the firm’s stock in a transaction dated Wednesday, April 13th. The shares were sold at an average price of $289.04, for a total value of $4,563,652.56. Following the transaction, the chairman now directly owns 74,160 shares of the company’s stock, valued at approximately $21,435,206.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ourania Tatsis sold 325 shares of the firm’s stock in a transaction dated Friday, February 25th. The shares were sold at an average price of $230.95, for a total transaction of $75,058.75. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,623 shares of company stock worth $13,527,514. Insiders own 0.70% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Pensionfund Sabic bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $2,525,000. Hudson Bay Capital Management LP grew its holdings in shares of Vertex Pharmaceuticals by 13.6% during the 3rd quarter. Hudson Bay Capital Management LP now owns 62,500 shares of the pharmaceutical company’s stock valued at $11,337,000 after purchasing an additional 7,500 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in Vertex Pharmaceuticals by 3.9% during the 3rd quarter. Janney Montgomery Scott LLC now owns 52,448 shares of the pharmaceutical company’s stock worth $9,514,000 after acquiring an additional 1,945 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG grew its holdings in Vertex Pharmaceuticals by 5.4% during the 3rd quarter. B. Metzler seel. Sohn & Co. Holding AG now owns 19,463 shares of the pharmaceutical company’s stock worth $3,530,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Meiji Yasuda Life Insurance Co grew its holdings in Vertex Pharmaceuticals by 16.1% during the 3rd quarter. Meiji Yasuda Life Insurance Co now owns 7,422 shares of the pharmaceutical company’s stock worth $1,346,000 after acquiring an additional 1,030 shares during the last quarter. 90.30% of the stock is currently owned by institutional investors.
Vertex Pharmaceuticals stock opened at $287.97 on Tuesday. The company has a market cap of $73.59 billion, a P/E ratio of 31.89, a price-to-earnings-growth ratio of 1.42 and a beta of 0.62. Vertex Pharmaceuticals has a 1-year low of $176.36 and a 1-year high of $292.75. The company has a fifty day simple moving average of $248.40 and a 200 day simple moving average of $219.45. The company has a current ratio of 4.46, a quick ratio of 4.30 and a debt-to-equity ratio of 0.05.
Vertex Pharmaceuticals Company Profile (Get Rating)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- UiPath Stock is Nearing Rock Bottom Down Here
- Array Technologies Stock Giving Another Ground Floor Entry
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.